Schulman (NHLBI) (estrogen-progestogen) 2002

NCT00000601

1 Treatments

Studied treatment intravenous estrogen followed by oral conjugated estrogen plus medroxyprogesterone for 21 days

Control treatment placebo

Concomitant treatments

Age (years) 69.7

2 Patients

Patients Postmenopausal women with unstable angina

Inclusion criteria Postmenopausal women (last menses >1 year before enrollment, previous bilateral oophorectomy or previous hysterectomy in women 55 years of age); presenting with an episode of UA within the prior 24 h

Exclusion criteria

type of prevention secondary

diabetes (%) 45%

hypertension (%) 76%

hyperlipidemia (%) -

BMI (kg/m²) -

Hysterectomy (%) -

Oophorectomy (%) -

3 Methods

Blinding double blind

Design Parallel groups

Centers -
**Geographical area**  USA, Brazil

**Sizes**  94/99

### 4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>-/9</td>
<td>-/99</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>venous thromboembolism</td>
<td>-/9</td>
<td>-/99</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>PE</td>
<td>-/9</td>
<td>-/99</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all cause death</td>
<td>-/9</td>
<td>-/99</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-/9</td>
<td>-/99</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV death</td>
<td>-/9</td>
<td>-/99</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>Coronary events (CHD)</td>
<td>-/9</td>
<td>-/99</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>non fatal MI</td>
<td>-/9</td>
<td>-/99</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

### 5 References